Research programme: chimeric antigen receptor T cell therapeutics - MabVax/MSKCC

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - MabVax/MSKCC

Alternative Names: CAR T-cell therapeutics - MabVax/MSKCC; CART cell therapies - MabVax/MSKCC

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
  • 31 May 2017 MabVax Therapeutics enters into a research agreement with Memorial Sloan Kettering Cancer Center for Pancreatic cancer, Small cell lung cancer and other Solid tumours
  • 10 Sep 2014 Early research in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top